Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T12:05:43.348Z.
Calculation as of: 2026-10-06T12:05:43.348Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.14B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.12B
EBITDA Yield
N/A
TTM Avg
3.55%
3Y Avg
3.10%
5Y Avg
3.10%
Market Cap
$1.12B
EBITDA Yield
11.34%
TTM Avg
12.87%
3Y Avg
11.35%
5Y Avg
9.45%
Market Cap
$1.16B
EBITDA Yield
12.02%
TTM Avg
13.63%
3Y Avg
7.88%
5Y Avg
6.04%
Market Cap
$1.20B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.14B | N/A | N/A | N/A | N/A |
| Castle Biosciences, Inc. (CSTL)vs › | $1.12B | N/A | 3.55% | 3.10% | 3.10% |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.12B | 11.34% | 12.87% | 11.35% | 9.45% |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.16B | 12.02% | 13.63% | 7.88% | 6.04% |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.20B | N/A | N/A | N/A | N/A |
| Cronos Group Inc. (CRON)vs › | $1.21B | 3.62% | 5.34% | 5.34% | 5.34% |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 7.73% | 4.52% | 2.41% | 2.41% |
| Damora Therapeutics, Inc. (DMRA)vs › | $1.24B | N/A | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $989.05M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $985.79M | N/A | 50.22% | 50.22% | 50.22% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
